Allogene Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-04-13$3.06 RISE2026-05-19$1.89 PEAK2026-05-27$2.25 44d | -38.2% 36d | Missed | Missed | — | — | +19.0% 8d | Missed |
DROP2025-12-11$1.55 RISE2025-12-30$1.31 PEAK2026-02-27$2.78 78d | -15.5% 19d | Missed | Missed | — | — | +112.2% 59d | Missed |
DROP2025-07-23$1.66 RISE2025-11-06$1.05 PEAK2026-02-02$1.87 194d | -36.7% 106d | Missed | Missed | — | — | +78.1% 88d | Missed |
DROP2025-05-02$1.70 RISE2025-08-12$1.03 PEAK2025-10-09$1.51 160d | -39.4% 102d | Missed | Missed | — | — | +46.6% 58d | Missed |
DROP2025-05-02$1.70 RISE2025-08-11$1.03 PEAK2025-10-09$1.51 160d | -39.4% 101d | Missed | Missed | — | — | +46.6% 59d | Missed |
DROP2025-02-19$2.60 RISE2025-06-30$1.13 PEAK2025-07-23$1.66 154d | -56.5% 131d | Missed | Missed | — | — | +46.9% 23d | Missed |
DROP2025-02-18$2.84 RISE2025-05-14$0.95 PEAK2025-07-23$1.66 155d | -66.5% 85d | Missed | Missed | — | — | +74.7% 70d | Missed |
DROP2024-11-06$3.22 RISE2025-02-11$1.40 PEAK2025-02-18$2.84 104d | -56.5% 97d | Missed | Missed | — | — | +102.9% 7d | Missed |
DROP2024-04-09$4.11 RISE2024-08-14$2.25 PEAK2024-11-06$3.22 211d | -45.3% 127d | Missed | Missed | — | — | +43.1% 84d | Missed |
DROP2024-03-06$5.63 RISE2024-07-03$2.08 PEAK2024-07-16$3.50 132d | -63.1% 119d | Missed | Missed | — | — | +68.3% 13d | Missed |
DROP2023-08-03$5.14 RISE2023-11-29$2.28 PEAK2024-02-27$5.14 208d | -55.6% 118d | Missed | Missed | — | — | +125.4% 90d | Missed |
DROP2023-02-17$7.20 RISE2023-06-29$4.58 PEAK2023-07-10$5.96 143d | -36.4% 132d | Missed | Missed | — | — | +30.1% 11d | Missed |
DROP2022-11-28$10.26 RISE2023-04-10$4.53 PEAK2023-05-15$6.74 168d | -55.8% 133d | Missed | Missed | — | — | +48.8% 35d | Missed |
DROP2022-08-25$15.59 RISE2022-12-27$5.62 PEAK2023-02-02$8.21 161d | -64.0% 124d | Missed | Missed | — | — | +46.1% 37d | Missed |
DROP2022-08-15$17.28 RISE2022-11-09$8.76 PEAK2022-11-25$10.77 102d | -49.3% 86d | Missed | Missed | — | — | +22.9% 16d | Missed |
1–15 / 24 1 / 2 | |||||||
No scored news yet for a sentiment trend.
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1, autologous CAR-T, allogeneic cell therapy, and antibody-drug conjugates. Below are the publicly traded category leaders in each. Each is a well-positioned standalone business ... Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Lead
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call May 13, 2026 5:00 PM EDTCompany ParticipantsChristine Cassiano - Executive VP, Chief Corporate...
Presentation Operator MessageOperator Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter 2026 Conference Call. [Operator Instructions] Please be aware that today's...
Allogene Therapeutics Inc (ALLO) reports encouraging interim trial results and strengthens its financial position with a successful public offering.
Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing. On the company’s quarterly conference call, President and Chief Executive Officer Dr. David
Allogene Therapeutics (NASDAQ:ALLO) released first-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://edge.media-server.com/mmc/p/nduedo4c/ Summary Allogene Therapeutics reported a strong cash position of $266.9 million as of March 31, 2026, with an additional $200.4 mi
Allogene Therapeutics saidon Wednesday it has ended a key partnership for developing celltherapies in parts of Asia and reworked its equity stake inpartner Overland Therapeutics. ...
-SEC Filing
Allogene Therapeutics Inc: Allogene Therapeutics Inc - enters termination agreement with Overland Therapeutics on May 12, 2026 - SEC filing Allogene Therapeutics Inc - terminates exclusive...
SOUTH SAN FRANCISCO, Calif. — SOUTH SAN FRANCISCO, Calif. — Allogene Therapeutics Inc. on Wednesday reported a loss of $42.6 million in its first quarter. The South San Francisco,...
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 35.71 percent increase over losses of $(0.28) per share
Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma ...
Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 -- Allogene Therapeutics, Inc. , a clinical-stage biotechnology company...
Natera, Inc. (NASDAQ:NTRA) is one of the Stocks that Billionaire Druckenmiller and Jim Cramer like. William Blair initiated coverage of Natera, Inc. (NASDAQ:NTRA) with an Outperform rating on the company’s stock on April 14, 2026. The firm recommends the stock as a core, long-term growth holding. William Blair highlights Natera, Inc. (NASDAQ:NTRA)’s leadership in major […]
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best biotech penny stocks to buy in 2026. On April 16, Allogene Therapeutics closed its underwritten public offering, raising $200.4 million in aggregate gross proceeds. The offering consisted of 87.5 million shares of common stock priced at $2.00 per share, plus an additional 12.7 million shares purchased […]
Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene Therapeutics received regulatory clearance to expand its pivotal Phase 2 ALPHA3 study of cemacabtagene ansegedleucel (cema-cel) into South Korea and Australia. This expansion increases the trial’s global footprint to over 80 sites, up from the […]
Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for more on LEGN stock.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ALLO | +0.93% | -18.11% | +58.39% | +85.47% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.04% | -12.40% | +61.84% | +72.78% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 8.66M | $21.13M | 0.00% | Added+213.6% | 2026-03-31 |
| TwoSigma | quant | 5.38M | $13.12M | 0.01% | Added+57.0% | 2026-03-31 |
| DEShaw | quant | 2.76M | $6.74M | 0.00% | Added+115.4% | 2026-03-31 |
| RenTech | quant | 2.14M | $5.22M | 0.01% | Trimmed-2.2% | 2026-03-31 |
| FidelityFMR | fundamental | 1.59M | $3.88M | 0.00% | Added+10.0% | 2026-03-31 |
| Citadel | multi-strat | 221.3K | $540.06K | 0.00% | Added+113.4% | 2026-03-31 |
| TRowePrice | fundamental | 5.38M | $13.13K | 0.00% | Added+67.7% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | -0.16 | — | — |
| 2026-05-13 | -0.18 | -0.18 | — |
| 2026-03-12 | -0.22 | -0.17 | +21.71% |
| 2025-11-06 | -0.23 | -0.19 | +18.69% |
| 2025-08-13 | -0.28 | -0.23 | +16.44% |
| 2025-05-13 | -0.29 | -0.28 | +5.08% |
| 2025-03-13 | -0.32 | -0.28 | +13.43% |
| 2024-11-07 | -0.33 | -0.27 | +19.52% |
| 2024-08-07 | -0.35 | -0.32 | +7.60% |
| 2024-05-13 | -0.41 | -0.38 | +6.41% |
| 2024-03-14 | -0.44 | -0.51 | -16.72% |
| 2023-11-02 | -0.52 | -0.37 | +28.75% |
| 2023-08-02 | -0.59 | -0.53 | +10.61% |
| 2023-05-03 | -0.62 | -0.68 | -9.79% |
| 2023-02-28 | -0.69 | -0.66 | +3.79% |
| 2022-11-02 | -0.65 | -0.58 | +10.87% |